Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2021

Autores

Ferreira da Silva, R (Autor) Outra; Inês Ribeiro-Vaz (Autor) Outra; Morato, M (Autor) FFUP; Jorge Junqueira Polónia (Autor) Outra

Revista

Título: International Journal of Clinical Pharmacy

ISSN: 2210-7703

Editora: Springer Nature

Indexação

ISI Web of Knowledge - 1 Citação

ISI Web of Science

Scopus - 2 Citações

Crossref

Pubmed / Medline

Google Scholar

Outras Informações

ID Authenticus: P-00T-ZYJ

DOI: 10.1007/s11096-021-01289-0

Abstract (EN): The COVID-19 pandemic presents several challenges to the organisation and workflow of pharmacovigilance centres as a result of the massive increase in reports, the need for quick detection, processing and reporting of safety issues and the management of these within the context of lack of complete information on the disease. Pharmacovigilance centres permanently monitor the safety profile of medicines, ensuring risk management to evaluate the benefit-risk relationship. However, traditional pharmacovigilance approaches of spontaneous reporting, are not suitable in the context of a pandemic; the scientific community and regulators need information on a near real-time point. The aim of this commentary is to suggest six interrelated multidimensional guiding axes for drug safety management by pharmacovigilance centres during the COVID-19 pandemic. This working plan can increase knowledge on COVID-19 and associated therapeutic approaches, support decisions by the regulatory authorities, oppose fake news and promote more efficient public health protection.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6